Status:

COMPLETED

Herpes Virus-6 and Epilepsy

Lead Sponsor:

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

Epilepsy

Eligibility:

All Genders

Brief Summary

This study will explore whether the human herpes virus-6 is associated with epileptic seizures. The virus may be involved in brain scarring, called mesial temporal sclerosis, which is seen in some epi...

Detailed Description

Objective: We would like to demonstrate with this study that the human herpesvirus-6 plays a role in the development of mesial temporal sclerosis (MTS) resulting in epilepsy. We would also like to exa...

Eligibility Criteria

Inclusion

  • Subjects of any race or ethnicity will be included in the study. Any subject who has been diagnosed with medically intractable epilepsy and is eligible for the epilepsy protocol #01-N-0139 will be evaluated for entry into this study.
  • INCLUSION CRITERIA:
  • All patients will have a seizure disorder as documented by EEG and video-EEG. Half of the patients will have radiologically documented mesial temporal sclerosis and the other half will have a brain MRI without mesial temporal sclerosis. The patients can only be on phenytoin, carbamazepine, oxcarbazepine, lamotrigine or levetiracetam, since these anti-epileptic drugs have the least or no effect on the glutamate and GABA levels in the brain. The patients can not take any other medications.
  • Healthy control subjects entering the study must be free of serious disease as determined by a standard physical and neurological examination. The control subjects can not be on any medication.
  • All subjects must be able to give informed consent allowing us to use the cerebrospinal fluid and serum for research.
  • All subjects will have to be able to refrain from chocolate, tea and coffee (low monoamine diet; Wood et al.1979) and alcohol during the one week before the study.
  • Patients must be seizure free for 48 hours prior to the lumbar tap and the MRS.
  • EXCLUSION CRITERIA
  • Subjects will be excluded if:
  • They are under the age of 18
  • They are female and are pregnant
  • They have a history of medical disorders which can affect the concentration of cerebral metabolites, including diabetes mellitus, renal dysfunction, hepatic dysfunction and electrolyte abnormality
  • They take any medication for the normal control group
  • They take any medication, with the exception of phenytoin, carbamazepine, oxcarbazepine, lamotrigine and levetiracetam for the epilepsy patients
  • They have a history of psychiatric and/or mood disorders
  • They have implanted devices such as pacemakers, medication pumps or defibrillators, or metal in the cranium except for the mouth, intra-cardiac lines, a history of shrapnel injury or any other condition/device that may be contraindicated or prevent the acquisition of MRI
  • They have a coagulopathy that prevents them from having a lumbar puncture performed
  • They have had a seizure 48 hours prior to the MRS and the lumbar tap
  • Subjects who cannot give informed consent allowing us to use the removed fluid for research will also be excluded.

Exclusion

    Key Trial Info

    Start Date :

    June 1 2004

    Trial Type :

    OBSERVATIONAL

    End Date :

    July 1 2005

    Estimated Enrollment :

    45 Patients enrolled

    Trial Details

    Trial ID

    NCT00085683

    Start Date

    June 1 2004

    End Date

    July 1 2005

    Last Update

    March 4 2008

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institute of Neurological Disorders and Stroke (NINDS)

    Bethesda, Maryland, United States, 20892